Logan Vander Woude, DO
Ophthalmology · Vero Beach, FLNPI 1972037018
Payments from drug & device makers
Across 171 payments — averaging $177.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$15K
- Bausch & Lomb Americas Inc.$11K
- AbbVie$1K
- NEW World Medical,inc.$999
- Johnson & Johnson Surgical Vision, Inc.$593
- Sight Sciences, Inc.$363
- plus $2K from 18 others
What the payments were for
- Consulting fees$7,40024%
- Speaking & faculty fees$390%
- Travel & lodging$2,3718%
- Food & beverage$6,64722%
- Education$30%
- Gifts$480%
- Other$13,80946%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 30 | $14,594 |
| Bausch & Lomb Americas Inc. | 21 | $10,673 |
| AbbVie(2 entities) | 33 | $1,032 |
| NEW World Medical,inc. | 20 | $999 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $593 |
| Sight Sciences, Inc. | 5 | $363 |
| Rxsight Inc | 5 | $296 |
| Glaukos Corporation | 4 | $289 |
| Ocular Therapeutix, Inc. | 11 | $241 |
| Dompe US, Inc. | 5 | $208 |
| Biotissue Holdings Inc. | 3 | $156 |
| Tarsus Pharmaceuticals, Inc. | 5 | $149 |
| Mallinckrodt Hospital Products Inc. | 5 | $142 |
| Mallinckrodt Enterprises LLC | 1 | $117 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $104 |
| Aerie Pharmaceuticals, Inc. | 1 | $100 |
| Boston Scientific | 2 | $64 |
| Amgen | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Harrow Eye, LLC | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$13,809
- Wavelight Refractive Suite$13,809
- Kahook Dual Blade$353
- Clearpath$353
- Ahmed Glaucoma Valve$353
- Streamline$353
- OMNI(R) SURGICAL SYSTEM (US)$273
- MIEBO$236
- XIIDRA$236
- Clareon$147
- RXSIGHT CONTACT LENS$144
- RXSIGHT INJECTOR CARTRIDGE$144
- RXSIGHT INJECTOR HANDPIECE$144
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$144
- LIGHT ADJUSTABLE LENS (LAL)$144
- DURYSTA$125
- Oxervate$122
- Via360$120
- iDose$120
- ACTIVEFOCUS$120
How this compares
$30,316 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 34 | $22,326 |
| LumiganBimatoprost | 49 | $21,247 |
| RhopressaNetarsudil Mesylate | 55 | $19,371 |
| RocklatanNetarsudil Mesylat/Latanoprost | 48 | $17,994 |
| Fluorometholone | 190 | $12,383 |
| Prednisolone Acetate | 235 | $11,574 |
| XiidraLifitegrast | 15 | $11,431 |
| Loteprednol Etabonate | 81 | $10,512 |
| MieboPerfluorohexyloctane/Pf | 11 | $8,088 |
| Cyclosporine | 14 | $5,288 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,290 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $4,105 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 25 | $3,498 |
| MoxifloxacinMoxifloxacin Hcl | 207 | $3,336 |
| ValacyclovirValacyclovir Hcl | 66 | $1,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,032 | $47,86394 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $100 | $37,364103 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $10,673 | $19,51926 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $104 | $10,51281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Vero Beach
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.